In patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations, erdafitinib (Balversa) in combination with cetrelimab displayed clinically meaningful responses.
Kyle Doherty
Articles by Kyle Doherty
Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.
Prospective clinical trial results of lutetium-PSMA suggest the therapy is safe for patients with locally advanced high-risk prostate cancer.
A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.
A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Data presented at the 2021 virtual ASCO Annual Meeting showed the benefits of adding nivolumab to chemotherapy treatment compared to chemotherapy alone, in patients with resectable non-small cell lung cancer.
The novel agent, zenocutuzumab demonstrated promise as treatment of patients with NRG1 fusion–positive cancers, in the phase 1/2 eNRGy study.
Progression-free survival and disease control in patients with advanced synovial sarcoma was improved by catequentinib.